Viewing Study NCT01167751



Ignite Creation Date: 2024-05-05 @ 10:41 PM
Last Modification Date: 2024-10-26 @ 10:22 AM
Study NCT ID: NCT01167751
Status: COMPLETED
Last Update Posted: 2016-06-21
First Post: 2010-07-19

Brief Title: Autologous Bone Marrow Derived Stem Cells for Acute Myocardial Infarction
Sponsor: Royan Institute
Organization: Royan Institute

Study Overview

Official Title: Autologous Bone Marrow Derived Ac 133 and Mono Nuclear Cells In-patient With Acute Myocardial Infarction During Coronary Artery Bypass Grafting CABG A Randomized Phase III Clinical Trial
Status: COMPLETED
Status Verified Date: 2010-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: One of the important reasons for human dying is Ischemic heart disease IHD The most reason is coronary artery disease Beside morbidity IHD induce myocardial infarction and necrosis which due to congestive heart failure

One therapeutic method is cellular cardiomyoplasty which is to produce and substitute the cardiac cells with stem cell transplantation Cell therapy is a potential therapeutic method to prevent ventricular remodeling after acute myocardial infarction Human and animal studies have shown that stem cell trans plantation to myocardial infarcted zone can improve heart contractile function

The aim of this study is to comparison the effects of BM-derived AC133 and MNC implantation in patients with myocardial infarction
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None